Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?

Graham, Brian B.; Hilton, Joan F.; Lee, Michael H.; Kumar, Rahul; Balladares, Dara Fonseca; Rahaghi, Farbod N.; Estépar, Raúl San José; Mickael, Claudia; Lima, Rodrigo Luís Barbosa; Loureiro, Camila M.C.; Lucena, Juliana; Oliveira, Rudolf K.F.; Corrêa, Ricardo de Amorim

doi:10.1016/j.jhlto.2023.100007

JHLT Open

2023

DOI: 10.1016/j.jhlto.2023.100007

|View full text |Cite

Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?

Brian B. Graham,

Joan F. Hilton,

Michael H. Lee

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Infection and pulmonary vascular diseases consortium: United against a global health challenge

Oliveira,

Almodóvar,

Butrous

et al. 2024

Pulm. circ.

View full text Add to dashboard Cite

Leveraging the potential of virtual platforms in the post‐COVID‐19 era, the Infection and Pulmonary Vascular Diseases Consortium (iPVDc), with the support of the Pulmonary Vascular Research Institute (PVRI), launched a globally accessible educational program to highlight top‐notch research on inflammation and infectious diseases affecting the lung vasculature. This innovative virtual series has already successfully brought together distinguished investigators across five continents – Asia, Europe, South and North America, and Africa. Moreover, these open global forums have contributed to a comprehensive understanding of the complex interplay among immunology, inflammation, infection, and cardiopulmonary health, especially concerning pulmonary hypertension and related pulmonary disorders. These enlightening discussions have not only heightened awareness about the impact of various pathogenic microorganisms, including fungi, parasites, and viruses, on the onset and development of pulmonary vascular diseases but have also cast a spotlight on co‐infections and neglected illnesses like schistosomiasis ‐ a disease that continues to impose a heavy socioeconomic burden in numerous regions worldwide. Thus, the overall goal of this review article is to present the most recent breakthroughs from infectious PVDs as well as bring to light the scientific and educational insights from the 2023 iPVDc/PVRI virtual symposium series, shaping our understanding of these crucial health issues in this more than ever interconnected world.

show abstract

Infection and pulmonary vascular diseases consortium: United against a global health challenge

Oliveira,

Almodóvar,

Butrous

et al. 2024

Pulm. circ.

View full text Add to dashboard Cite

show abstract

Treatment algorithm for pulmonary arterial hypertension

Chin,

Gaine,

Gerges

et al. 2024

Eur Respir J

View full text Add to dashboard Cite

Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right heart function, exercise capacity, quality of life and survival. Current therapies have mechanisms of action involving signallingviaone of four pathways: endothelin-1, nitric oxide, prostacyclin and bone morphogenetic protein/activin signalling. Efficacy has generally been greater with therapeutic combinations and with parenteral therapy compared with monotherapy or nonparenteral therapies, and maximal medical therapy is now four-drug therapy. Lung transplantation remains an option for selected patients with an inadequate response to therapies.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Is pulmonary arterial hypertension associated with schistosomiasis distinct from pulmonary arterial hypertension associated with portal hypertension?

Cited by 2 publications

References 56 publications

Infection and pulmonary vascular diseases consortium: United against a global health challenge

Infection and pulmonary vascular diseases consortium: United against a global health challenge

Treatment algorithm for pulmonary arterial hypertension

Contact Info

Product

Resources

About